Literature DB >> 21690444

Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center.

Johnny C Hong1, Christopher M Jones, John P Duffy, Henrik Petrowsky, Douglas G Farmer, Samuel French, Richard Finn, Francisco A Durazo, Sammy Saab, Myron J Tong, Jonathan R Hiatt, Ronald W Busuttil.   

Abstract

OBJECTIVES: To compare the survival difference between 2 surgical modalities in the treatment of locally advanced intrahepatic and hilar cholangiocarcinoma (CCA) and to identify factors that predict mortality.
DESIGN: Retrospective study.
SETTING: University transplant center. PATIENTS: Of the 132 patients with a diagnosis of CCA treated from February 1, 1985, through June 30, 2009, 75 had metastatic disease at presentation and were excluded from the study, whereas 57 patients were candidates for surgical therapy. Tumor type was intrahepatic in 37 patients and hilar in 20 patients. Surgical therapy included orthotopic liver transplant (OLT) in 38 patients and combined radical bile duct resection with partial hepatectomy (RR) in 19 patients.
RESULTS: Tumors were locally advanced in 35 of 37 patients (95%) with intrahepatic tumors and 16 of 20 patients (80%) with hilar tumors. Adjunctive therapy was used in 35 patients (61%). The 5-year tumor recurrence-free patient survival was significantly higher in the OLT group compared with the RR group (33% vs 0%; P = .05). In the OLT group, neoadjuvant and adjuvant therapies resulted in better patient survival compared with no therapy or adjuvant therapy only (47% vs 20% vs 33%, respectively; P = .03). Multivariate factors predictive of worse survival outcomes included hilar CCA, multifocal tumors, perineural invasion, and RR as the treatment modality compared with OLT. Tumor sizes--5 cm or larger for intrahepatic and 3 cm or larger for hilar CCA--were not predictors of poor outcome.
CONCLUSION: Orthotopic liver transplant in combination with neoadjuvant and adjuvant therapies is superior to RR with adjuvant therapy in locally advanced intrahepatic and hilar CCA.

Entities:  

Mesh:

Year:  2011        PMID: 21690444     DOI: 10.1001/archsurg.2011.116

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  56 in total

1.  Hilar cholangiocarcinoma: expert consensus statement.

Authors:  John C Mansour; Thomas A Aloia; Christopher H Crane; Julie K Heimbach; Masato Nagino; Jean-Nicolas Vauthey
Journal:  HPB (Oxford)       Date:  2015-08       Impact factor: 3.647

Review 2.  Liver transplantation for hilar cholangiocarcinoma.

Authors:  Ricardo Robles; Francisco Sánchez-Bueno; Pablo Ramírez; Roberto Brusadin; Pascual Parrilla
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

3.  Intrahepatic cholangiocarcinoma.

Authors:  Kimberly M Brown; Abhishek D Parmar; David A Geller
Journal:  Surg Oncol Clin N Am       Date:  2014-04       Impact factor: 3.495

Review 4.  Surgical options for intrahepatic cholangiocarcinoma.

Authors:  Kui Wang; Han Zhang; Yong Xia; Jian Liu; Feng Shen
Journal:  Hepatobiliary Surg Nutr       Date:  2017-04       Impact factor: 7.293

Review 5.  Therapeutic options for intrahepatic cholangiocarcinoma.

Authors:  Manojkumar Bupathi; Daniel H Ahn; Tanios Bekaii-Saab
Journal:  Hepatobiliary Surg Nutr       Date:  2017-04       Impact factor: 7.293

Review 6.  [Indications for transplantation and bridging procedures for primary hepatobiliary malignancies].

Authors:  J Mittler; S Heinrich; H Lang
Journal:  Chirurg       Date:  2018-11       Impact factor: 0.955

Review 7.  Liver transplantation in the management of perihilar cholangiocarcinoma.

Authors:  Aliya F Gulamhusein; William Sanchez
Journal:  Hepat Oncol       Date:  2015-11-06

Review 8.  Epidemiology and surgical management of intrahepatic cholangiocarcinoma.

Authors:  Han Zhang; Feng Shen; Jun Han; Yi-Nan Shen; Guo-Qiang Xie; Meng-Chao Wu; Tian Yang
Journal:  Hepat Oncol       Date:  2015-11-30

Review 9.  Liver Transplantation for Cholangiocarcinoma: Insights into the Prognosis and the Evolving Indications.

Authors:  Guergana G Panayotova; Flavio Paterno; James V Guarrera; Keri E Lunsford
Journal:  Curr Oncol Rep       Date:  2020-04-16       Impact factor: 5.075

Review 10.  Multimodal treatment strategies for advanced hilar cholangiocarcinoma.

Authors:  Matthew J Weiss; David Cosgrove; Joseph M Herman; Neda Rastegar; Ihab Kamel; Timothy M Pawlik
Journal:  Langenbecks Arch Surg       Date:  2014-06-25       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.